Many sectors have been hit by the virtual disappearance of initial public offerings to fund their operations, but biotech, which is generally in a pre-revenue stage as it develops and tests a new drug, is particularly vulnerable. We explain why below:
To read the entire story, you must be logged in.
Please log in now or register with us.
